Analysts say MDS' deal to buy Molecular Devices for $615 million represents a "healthy premium" for investors. MDS plans to combine Sunnyvale, CA-based Molecular Devices, which makes software and systems for researchers engaged in biochemical testing and cellular analysis, with MDS Sciex into a unit with 1,100 employees. The unit will be led by Andy Boorn. MDS is paying $35.50 a share, a 49 percent premium over the January 26 closing price. MDS says that the FDA is close to wrapping up a long and expensive review of its research centers after the agency cited the company for failing to fix the sources of contamination found in blood tests.